Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Innovating New Technologies and Therapeutics in The Field of COPD and Lung Health
- COPD 2020

Welcome Message

The 7th International Conference on COPD and Lung Health welcomes PulmonologistsRespiratory Medicine specialists, Researchers and Students across the globe to discuss current trends in respiratory disease screening to diagnosis, treatment and management. Strategic sessions of the COPD and Lung Health will encompass recent researches and findings in Respiratory Diseases such as COPD, asthma, tuberculosis, vaping, cystic fibrosis, pneumonia, emphysema, lung cancer, pulmonary fibrosis, sleep apnea, interstitial lung disease, bronchiectasis, chronic cough, influenza, mycobacterial infection etc. COPD 2020 will be featuring the world class keynote talk, speakers presenting clinical studies, oral and poster presentation with interactive networking session and workshops. Every part of this conference is focused on sharing new research works with the eminent personalities.

COPD 2020 Conference will enlighten the world with recent advances in COPD and lung health research and inculcate new ideas about healthy breathing. Moreover, COPD 2020 Conference provides the participants a great networking with peers. We encourage physicians, nurses, researchers and scientists as well as patients in the respiratory field and those interested in attending COPD 2020. It is only through an exchange of the widest variety of research we can offer the best program and benefits to our members and patients.

Abstract Submission & Important Dates

Abstract Submission Guidelines: 

The length of the abstract must not exceed 300 words.

The title should be in sentence case.

Should write name of the author and co-authors (if any).

You must provide your full name, affiliation (degree, institution/company/University name, address, contact number and email address).

Short biography of the author (limited to 100 words).

They must be submitted before the deadlines.

All the abstracts will be reviewed by the committee and you will get an email within 24-48 hours after submission of your abstract.

All the accepted abstracts will be published in the conference proceeding books.

Submit your Abstracthttp://copd.alliedacademies.com/abstract-submission

Register now: http://copd.alliedacademies.com/registration

Sessions and Tracks

Sessions and Tracks
Session 1: Respiratory Disorders
Respiratory disorder is a term that encompasses a variety of pathogenic conditions that affect respiration in living organisms. Respiration involves gas exchange in higher organisms. Respiratory disorders occur in the respiratory tract, which includes the alveoli, bronchi, bronchioles, pleura, pleural cavity, trachea and the nerves and muscles of breathing. Respiratory disorders or lung diseases include COPD, asthma, cystic fibrosis, emphysema, lung cancer, interstitial lung disease, mesothelioma, pulmonary hypertension, tuberculosis, alpha-1antitrypsin deficiency, bronchiectasis, idiopathic pulmonary fibrosis, pneumonia, respiratory failure, respiratory distress syndrome, sarcoidosis, sleep apnea, sleep deprivation and deficiency, influenza and many more. If left untreated, lung disease can produce health complications and life-threatening conditions.

Session 2: COPD

Chronic Obstructive Pulmonary Disease is a progressive disease that causes airflow blockage and breathing-related problems. It can cause coughing that produces large amounts of a slimy substance called mucus, wheezing, shortness of breath as well as chest tightness. Cigarette smoking is the leading cause of COPD. Long-term exposure to other lung irritants such as air pollution, chemical fumes, or dusts also contribute to COPD. A rare genetic condition called alpha-1 antitrypsin (AAT) deficiency can also lead to COPD. COPD cannot be cured but it can be treated to lower the chance of complications, and generally improve quality of life. Clinical symptoms and signs, such as abnormal shortness of breath and increased forced expiratory time, can be used to help with the diagnosis of COPD. Medications, supplemental oxygen therapy and surgery are some forms of treatment.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 3: Lung Function and Its Genetics

Several family studies have provided evidence for familial resemblance of pulmonary function measures. Studies have consistently shown significant parent-offspring and sibling-sibling correlations in lung volume and flow rate measures. Genetic factors may have different influences on phenotypes of airway function, lung volume, and airway-parenchymal dysanapsis. Aetiological heterogeneity may exist in families with COPD or asthma and heredity may have different effects on normal airway function and on airway dysfunction. Genetics, lifestyle and environmental factors play a role in the development of lung diseases.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 4: Vaping Induced Lung Injury

Vaping is the most popular form of tobacco used among teenagers. An electronic cigarette is a battery-operated device that emits doses of vaporized nicotine, or non-nicotine solutions, for the user to inhale. It aims to provide a similar sensation to inhaling tobacco smoke, without the smoke. Vaping side effects can be from short-term, minor issues to something so severe that might lead to death of a person. Side effects of vaping include, dry mouth, dizziness, cough, dry skin, itchiness, dry eyes, insomnia, nosebleeds. E-cigarette vapor increases inflammation and disables cells that protect lung tissue. Harming these cells makes them vulnerable to dust, bacteria and allergens that might lead to incurable chronic obstructive pulmonary disease (COPD).


COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 5: Comorbidities of COPD

Tobacco smoking is a common risk factor for many comorbidities Comorbidities such as pulmonary artery disease and malnutrition are directly caused by COPD. Cardiovascular, metabolic, musculoskeletal and psychological comorbidities contribute to the morbidity and mortality in all stages of COPD. Comorbidities commonly associated with chronic obstructive pulmonary disease are hypertension, coronary artery disease, systolic and/or diastolic left ventricular dysfunction, pulmonary hypertension, peripheral vascular disease, depression, anxiety, cognitive impairment, anemia, obstructive sleep apnea, diabetes/metabolic syndrome, renal insufficiency, lung cancer and infections.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 6: Lung Cancer Diagnosis & Treatment


Lung cancer is a condition that causes cells to divide in the lungs uncontrollably which leads to the growth of tumors that reduce a person's ability to breathe. Symptoms of lung cancer include appetite loss, changes to a person's voice, such as hoarseness, frequent chest infections, such as bronchitis or pneumonia, lingering cough that may start to get worse, shortness of breath, unexplained headaches, weight loss and wheezing. Early diagnosis of lung cancer can be lifesaving because lung cancer cells can travel to other areas of the body before a doctor detects them in the lungs. If metastasis has taken place, it makes treating the disease much more difficult. Treatment for lung cancer depends on its location and stage, as well as the overall health of the individual. Possible treatments include surgery, chemotherapy, radiation therapy and targeted therapy.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 7: Alpha 1 Antitrypsin Deficiency & Lung Disease

Alpha-1 antitrypsin deficiency is a genetic disorder that is passed on in families and affects the lungs, liver and skin. When this condition affects the lungs, it causes COPD. There is no cure, but treatment can help people with Alpha-1 antitrypsin deficiency manage their symptoms and live a better life. The earliest symptoms are shortness of breath following mild activity, reduced ability to exercise, and wheezing. Other signs and symptoms include unintentional weight loss, recurring respiratory infections, fatigue, and rapid heartbeat upon standing. Affected individuals often develop emphysema, which is a lung disease caused by damage to the small air sacs in the lungs. Alpha-1 antitrypsin deficiency accounts for 1 to 2% of all cases of chronic obstructive pulmonary disease.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 8: Tuberculosis

Tuberculosis (TB) is a serious infectious disease that mainly affects the lungs and it is caused by bacteria (Mycobacterium tuberculosis). The bacteria that cause tuberculosis are spread from one person to another through tiny droplets released into the air via cough and sneeze. Tuberculosis can be fatal when it is untreated. Untreated active disease typically affects the lungs, and it can spread to other parts of the body through the blood stream. Complications of tuberculosis include spinal pain, joint damage, swelling of the membranes that cover the brain, liver or kidney problems and heart disorders. People diagnosed with active TB disease generally have to take a combination of medications for six to nine months. A substantial number of TB patients develop post tubercular airway disease or TB-associated COPD.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 9: Asthma

 

Asthma is a clinical syndrome of chronic airway inflammation characterized by recurrent and reversible airway obstruction. Most people with asthma will not develop COPD, however, it’s possible to have both. Asthma-COPD overlap syndrome (ACOS) occurs when someone has these two diseases at a time. Signs of ACOS include difficulty in breathing, wheezing, frequent coughing, excess phlegm, feeling tired, low physical tolerance for exercise, shortness of breath during routine activities. Common triggers for asthmatic symptoms include exposure to allergens (dust mites, cockroach, molds and pollens), exercise and viral infections. Most people who have asthma are treated with daily medicine, called long-term control medicines, along with inhalers containing medicine for short-term relief.


COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 10: Pneumonia

 

Pneumonia is an infection that inflames the air sacs in the lungs. It is most serious for infants and young children, people older than age 65, and people with weakened immune systems. Bacterial pneumonia, is the most common form, tends to be more serious than other types of pneumonia. The symptoms of bacterial pneumonia can develop gradually. In few cases pneumonia can be difficult to diagnose because the symptoms are so variable and are often very similar to those seen in a cold or influenza. Complications of pneumonia are as follows: pleural effusion, empyema, lung abscess, bacteremia, septicemia, meningitis, septic arthritis, endocarditis or pericarditis.


COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 11: Cystic Fibrosis

Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time and it affects the cells that produce mucus, sweat and digestive juices. It is caused by a change, or mutation, in a gene called CFTR (cystic fibrosis transmembrane conductance regulator). This gene controls the flow of salt and fluids in and out of the cells. The thick and sticky mucus associated with cystic fibrosis clogs the tubes that carry air in and out of the lungs. This can cause signs and symptoms such as persistent cough that produces thick mucus, wheezing, breathlessness, exercise intolerance, repeated lung infections, inflamed nasal passages or a stuffy nose. Cystic fibrosis is one of the leading causes of bronchiectasis, a condition that damages the airways and this makes it harder to move air in and out of the lungs and clear mucus from the airways. Overtime, lung function usually worsens gradually, and it eventually can become life-threatening.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 12: Sleep Apnea

Sleep apnea is a sleep disorder that occurs when a person's breathing is interrupted during sleep. If left untreated, sleep apnea can increase the risk of health problems, such as high blood pressure, stroke, heart failure, irregular heartbeats, and heart attacks, diabetes, depression, worsening of ADHD, Headaches. Depending on the cause and the level of apnea, there are different methods of treatment and the goal of treatment is to normalize breathing during sleep. Treatment options for obstructive sleep apnea include: Continuous Positive Airflow Pressure (CPAP), other breathing devices, oral appliances, implants and surgery.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 13: Cardiopulmonary Disease

Cardiopulmonary disease is the medical term used to describe a range of serious disorders that affect the heart and lungs. The two-primary tobacco-related cardiopulmonary diseases are Cardiovascular Disease (CVD) and Chronic Obstructive Pulmonary Disorder (COPD). Early identification and treatment of cardiopulmonary disease is crucial for reversing organ damage and preventing further injury to the organs. E-cigarettes produce ultra-fine particulate matter and cytotoxic chemicals, which are known to negatively impact heart and lung function, respectively. Nicotine itself is known to impair lung function, particularly in adolescents

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 14:  Pulmonary Rehabilitation

Pulmonary Rehabilitation is an exclusive program for education and exercise that helps to manage the breathing problems, increase the alveolar capacity for breathing, increase the energy of the individual and reduce the breathlessness. This program isolates the individual from using any of the harmful substances like tobacco, ganja or cannabis, etc. and rehabilitates them. The patients suffer a lot of pain and withdrawal symptoms. The staff assists them to exercise to bring ability to withstand and the muscle strength builds up. Breathing sessions and regular counseling sessions will also happen to make their mind and body prevent the thoughts of using the harmful substances.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 15: Pathology and Clinical Management of COPD

The predominant pathologic changes of COPD are found within the airways; however, changes are seen within the lung parenchyma and pneumonic vasculature. In an individual, the pattern of pathologic changes depends on the underlying illness (e.g., bronchitis, emphysema, alpha-1 antitrypsin deficiency), presumably individual susceptibility, and illness severity. While radiographic strategies don't have the resolution of microscopic anatomy, high resolution computerized axial tomography can assess lung parenchyma, airways, and pneumonic vasculature. About 62 % of patients with moderate to severe COPD report variability in symptoms (e.g., dyspnea, cough, sputum, wheezing, or chest tightness) over the course of the day or week-to-week; morning is usually the worst time of day. An effective COPD management plan includes four components: assess and monitor the disease; reduce the risk factors; manage and stabilize COPD; manage the exacerbations. The most important factor for the COPD is cigarette smoking. The clinical management techniques involved to reduce the exacerbation of these factors that affect COPD must be developed in an efficient way.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 16: Diagnosis and Treatment of COPD


The main test for diagnosing COPD is a lung function test called spirometry which involves the use of a machine called a spirometer that measures how much air you are able to move by taking a deep breath in and out, and how quickly you are able to do so. Arterial blood gas analysis is second important test in diagnosing COPD. This test measures how much oxygen and carbon dioxide are present in the blood. A high percentage of carbon dioxide in the blood can be a sign of poorly functioning lungs. Pharmacotherapy and smoking cessation are the important methods of treatment, while pulmonary rehabilitation, long-term oxygen therapy, and surgery may be considered in selected patients. Steroids, inhalers and antibiotics may be prescribed to treat various symptoms of COPD. Smoking cessation is the most effective intervention in stopping the progression of COPD, as well as increasing survival rate of persons suffering with COPD. Therefore, smoking cessation should be the top priority in the treatment of COPD.


COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology

Session 17: Digital Health in Respiratory Care

Everyday life is increasingly influenced by digitization. Digital health technology promises to facilitate a patient-centered care model for the management of COPD by empowering patients to self-manage effectively and presently, it is not widely used in medicine. For pulmonology, digitization offers opportunities and risks in different areas like obstructive lung diseases, thoracic oncology, pulmonary rehabilitation, sleep medicine, home mechanical ventilation, and in intensive care medicine. One of the opportunities is that the use of new technologies such as medical apps and the analysis of this new support make it possible to better understand and manage diseases. One of the key advantages is the use of "big data" for displaying dynamic behavior to better understand disease processes, and to optimize patient management by using analytic techniques such as machine learning. Risks to be considered are data privacy and security as well as the use of artificial intelligence. To address the need for optimized adherence to maintenance medication in patients with respiratory diseases, several digital technologies have been developed. Strategies used to date include approaches to monitoring and improving adherence, such as electronic inhalers, text messaging and reminders, and self-management tools.

COPD Conferences | Conferences on Lung Health | Meetings on Pulmonary Diseases | Pulmonology Conferences | Top COPD Conferences | Lung Health Conferences | World COPD Congress | Congress on COPD | COPD | Lung Diseases | Respiratory Diseases | Pulmonology 

Market Analysis

Globally, asthma and COPD are one of the leading chronic respiratory diseases, with high prevalence and increasing health care and economic burden. They are either genetically acquired or caused due to several environmental factors. The global market for Asthma & COPD has been analyzed based on drugs and devices which are used for these diseases. Currently, North America leads the global market for asthma & COPD drugs and devices, and it was followed by Europe in terms of market capitalization. Growing aging population along with increasing automotive and industrial exhaust gases have remained the key drivers for the global asthma and COPD market. Degrading air quality near the industrial areas has led to the increased incidence of asthma in the low-income population in the emerging economies of China, India, Brazil and Russia.

COPD is rated to be the fourth most common cause of mortality, and expected to reach third position by 2030, in case the risks such as smoking, pollution is not addressed. There is a rise in the prevalence of asthma and COPD in both developed and developing countries. In developed countries, the rise in prevalence is mainly due to lifestyle change such as smoking, while in developing countries rise is observed due to presence of most polluted cities in the world and inclusion of smoking in day to day lifestyle. Global COPD drugs market size will grow by almost USD 3.52 billion during 2019-2023, at a CAGR close to 4% due to the success of combination therapies.

The biggest COPD market in the Asia Pacific are Australia, China, India, Japan, and South Korea, followed by the rest of the Asia Pacific. In the MEA region, the market is small due to poor or limited infrastructure and less investment in health care. Overall, the COPD mortality rate for men and women in Europe, age-standardized to the European Standard Population, is about 18 per 100 000 inhabitants per year. In the WHO-defined European region, one in ten deaths are caused by either chronic obstructive pulmonary disease (COPD), lung cancer, tuberculosis, or a lower respiratory tract infection such as pneumonia.

The burden of chronic obstructive pulmonary disease (COPD) is increasing in the USA and its prevalence is now almost equal in males and females. Approximately 7% of the adult population in the USA has low lung function and 70% of these adults have never had a diagnosis of obstructive lung disease.  

Europe is predicted to be the second-largest lung cancer therapeutics market, owing to the growing cancer prevalence, favorable government funding in the field of research, analysis, development of innovative medication, presence of developed healthcare infrastructure, and technological growth related to cancer. Germany, France, and U.K. are major countries in the European lung cancer therapeutics market.



Organizing Committee
OCM Member
Bushra Mina
Section Chief, Pulmonary Medicine at Lenox Hill Hospital
Lenox Hill Hospital | Northwell Health's
New York, USA
OCM Member
Dejan Dokic
Director, University Clinic of Pulmonology and Allergy
Sts Cyril and Methodius
Skopje, Macedonia
OCM Member
Dr. John Klir
American International Medical University
Washington, USA
OCM Member
Javier Mauricio Giraldo Sánchez
Doctor, Internal medicine
Medicina Intensiva del Tolima UCI Honda
Bogota, Colombia
OCM Member
Dr Marousa Kouvela
Pulmonologist, Medical Manager Respiratory
Boehringer-Ingelheim Ellas
Athens, Greece
OCM Member
Joe Nemeth
Doctor, McGill University Health Centre
McGill University
Kelowna, Canada
Renowned Speakers

To Collaborate Scientific Professionals around the World

Conference Date October 19-20, 2020
Speaker Oppurtunity Day 1 Day 2
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Sponsorship Opportunities Click here for Sponsorship Opportunities
Venue
&
Hospitality


    Join The Discussion

    Allied Academies Global Conference Directory

    Mail us at

    Program Manager
    copd@alliedmeetings.com
    Sponsorship / Exhibitor Opportunity
    reachus@conferencesmeet.com
    General Information
    enquire@conferencesmeet.com
    More details about sponsorship:sponsors@alliedacademies.com

    Terms and Conditions

    Responsibility

    Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.

    Insurance

    Registration fees do not include insurance of any kind.

    Transportation

    Please note that any (or) all transportation and parking is the responsibility of the registrant.

    Press/Media

    Press permission must be obtained from Allied Academies Conferences Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies Ltd is an objective third-party nonprofit organization. This conference is not associated with any commercial meeting company.

    Requesting an Invitation Letter

    For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact copd@alliedglobalevents.com to request a personalized letter of invitation.

    Regarding refunds, all bank charges will be for the registrants account.

    Cancellation, Postponement and Transfer of Registration

    All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

    • Within 90-60 days of Conference: Eligible for 50% of payment Refund
    • Within 60 days of Conference: Not eligible for Refund
    • E-Poster Payments will not be refunded.

    Cancellation Policy

    If Allied Academies Group cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Group event which must occur within one year from the date of cancellation.

    Postponement

    If Allied Academies Group postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Ltd event which must occur within one year from the date of postponement.

    Transfer of registration

    All fully paid registrations are transferable to other persons from the same organization if the registered person is unable to attend the event. Transfers must be made by the registered person in writing to finance@alliedacademies.com
    . Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

    Registration can be transferred to one conference to another conference of Allied Academies Ltd if the person is unable to attend one of the conferences.

    However, Registration cannot be transferred if it is intimated within 14 days of the respective conference.

    The transferred registrations will not be eligible for Refund.

    Visa Information

    Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

    Allied Academies Ltd will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

    Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies Ltd, including the inability to obtain a visa.

    Refund Policy

    If the registrant is unable to attend and is not able to transfer his/her participation to another person or event, then the following refund arrangements apply:

    Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

    Accommodation Cancellation Policy

    Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies Ltd will advise the cancellation policy of your accommodation provider, prior to cancelling or amending your booking, to ensure you are fully aware of any non-refundable deposits.

    Highlights from last year's Convention

    Authorization Policy

    Copyright © 2020-2021 Allied Academies, All Rights Reserved.